c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
The aim of this study was to explore the difference in c-Met expression between primary and recurrent glioblastoma multiforme (GBM), and to determine whether the dysregulation of c-Met expression has a role in the malignant progression of GBM. Paired primary and recurrent GBM specimens from the same patient were evaluated using immunohistochemical analysis. The association between c-Met expression and progression-free survival time (PFST) was analyzed. There was a significant difference in c-Met expression between primary and recurrent tumors (p=0.020), and patients with tumors expressing c-Met at a higher level had a significantly shorter PFST (6.1 months vs. 11.5 months; p=0.026). Our study indicates that recurrent GBM express c-Met at a higher level and that c-Met overexpression is associated with shorter PFST in patients with GBM. These findings suggest that c-Met potentially has an important role in the treatment of GBM.
Liu
Wei
W
Department of Neurosurgery, Provincial Hospital affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong 250021, China.
Fu
Yibing
Y
Xu
Shangchen
S
Ding
Feng
F
Zhao
Guangyu
G
Zhang
Kang
K
Du
Chigang
C
Pang
Bo
B
Pang
Qi
Q
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism*
D019859:Proto-Oncogene Proteins c-met